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Abstract
Adenoid cystic carcinoma of the breast is a rare histologic type of triple-negative breast cancer 
with an indolent clinical behavior, often driven by the MYB-NFIB fusion gene. Here we sought to 
define the repertoire of somatic genetic alterations in two adenoid cystic carcinomas associated 
with high-grade triple-negative breast cancer. The different components of each case were 
subjected to copy number profiling and massively parallel sequencing targeting all exons and 
selected regulatory and intronic regions of 488 genes. Reverse transcription PCR and fluorescence 
in situ hybridization were employed to investigate the presence of the MYB-NFIB translocation. 
The MYB-NFIB fusion gene was detected in both adenoid cystic carcinomas and their associated 
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high-grade triple-negative breast cancer components. Whilst the distinct components of both cases 
displayed similar patterns of gene copy number alterations, massively parallel sequencing analysis 
revealed intra-tumor genetic heterogeneity. In case 1, progression from the trabecular adenoid 
cystic carcinoma to the high-grade triple-negative breast cancer was found to involve clonal shifts 
with enrichment of mutations affecting EP300, NOTCH1, ERBB2 and FGFR1 in the high-grade 
triple-negative breast cancer. In case 2, a clonal KMT2C mutation was present in the cribriform 
adenoid cystic carcinoma, solid adenoid cystic carcinoma and high-grade triple-negative breast 
cancer components, whereas a mutation affecting MYB was present only in the solid and high-
grade triple-negative breast cancer areas and additional three mutations targeting STAG2, KDM6A 
and CDK12 were restricted to the high-grade triple-negative breast cancer. In conclusion, adenoid 
cystic carcinomas of the breast with high-grade transformation are underpinned by MYB-NFIB 
fusion gene, and, akin to other forms of cancer, may be constituted by a mosaic of cancer cell 
clones at diagnosis. The progression from adenoid cystic carcinoma to high-grade triple-negative 
breast cancer of no special type may involve the selection of neoplastic clones and/ or the 
acquisition of additional genetic alterations.
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INTRODUCTION
Adenoid cystic carcinoma of the breast is a rare special histologic type of breast cancer, 
accounting for <1% of all cases of invasive disease.1,2 Adenoid cystic carcinomas are 
characterized by a dual population of neoplastic epithelial and myoepithelial cells, arranged 
in cribriform, tubular, trabecular or solid patterns.1,3 Like other salivary gland-like tumors 
occurring in the breast, breast adenoid cystic carcinomas almost invariably display a triple-
negative phenotype (i.e. lack of estrogen receptor (ER), progesterone receptor (PR), and 
HER2 expression). At variance with common forms of triple-negative breast cancer, adenoid 
cystic carcinomas of the breast generally have an indolent clinical course with a 10-year 
overall survival rate of about 90%.1,3–5
At the genetic level, adenoid cystic carcinomas are characterized by the t(6;9)(q22–23;p23–
24) translocation, resulting in the MYB-NFIB gene fusion,6,7 which is considered an early 
event in the tumorigenesis of these lesions.7–9 More recently, rearrangements affecting 
MYBL1 have also been documented in a subset of MYB-NFIB-negative adenoid cystic 
carcinomas.10,11 In contrast to common forms of triple-negative breast cancer, which are 
characterized by complex genomes and high mutation rates, breast adenoid cystic 
carcinomas have been shown to have rather simple genomes with low levels of genetic 
instability and low mutation rates.7,12,13,14–16 In fact, adenoid cystic carcinoma lack somatic 
mutations found in common types of triple-negative breast cancer, including TP53 and 
PIK3CA,16 but display a heterogeneous constellation of non-synonymous somatic mutations 
affecting cancer-related genes that converge into several functional categories, including 
chromatin remodeling and cell adhesion.12,13
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High-grade transformation of salivary gland adenoid cystic carcinomas has been 
reported;17,18 this phenomenon, however, has also been documented in breast adenoid cystic 
carcinomas,19–21 where it presents as adenoid cystic carcinomas with solid architectural 
patterns and areas with histologic features consistent with those of high-grade triple-negative 
breast cancers of no special type. The genetic events associated with the progression from 
conventional breast adenoid cystic carcinoma to high-grade triple-negative breast cancer of 
no special type remain to be elucidated. The aim of this study was to define whether the 
high-grade triple-negative breast cancers associated with breast adenoid cystic carcinomas 
are clonally related and to investigate the pattern of somatic genetic alterations of breast 
adenoid cystic carcinomas showing progression to high-grade triple-negative breast cancers.
PATIENTS AND METHODS
Clinicopathologic characteristics
Two patients with diagnosis of adenoid cystic carcinoma of the breast with heterogeneous 
morphology and associated with areas of high-grade triple-negative breast cancer were 
included in the study. Patient 1 (AdCC1) was a 40-year-old woman with a nodule of 1.9 cm 
in the upper quadrants of the right breast. No other relevant clinical conditions or family 
history were documented. An excisional biopsy was performed at the Indiana University 
Hospital, IN, USA, and a diagnosis of trabecular adenoid cystic carcinoma with a solid 
component was rendered. Unequivocal areas of high-grade triple-negative breast cancer 
were not observed. A total mastectomy with sentinel lymph node excision was performed. 
Histologic examination revealed a multifocal high-grade triple-negative breast cancer of no 
special type, and no additional areas diagnostic of adenoid cystic carcinoma were present. 
All sentinel lymph nodes were negative. Immunohistochemical analysis revealed that all 
lesions displayed a triple-negative phenotype. After 58 months of follow-up, the patient is 
alive and free of disease.
Case 2 (AdCC2) was a 36 year-old woman who underwent a wide local excision at the Kato 
Breast Surgery Clinic, Japan, for a 3.5 cm nodule of the upper quadrant of the right breast. 
Histologic examination revealed a triple-negative breast cancer consistent with adenoid 
cystic carcinoma but the tumor showed high-grade triple-negative breast cancer areas. All 
sentinel lymph nodes were negative. Since the lesion was focally present on one surgical 
margin, the patient underwent adjuvant radiotherapy. A combination of paclitaxel and 
doxifluridine was also delivered. After 8 years of follow-up, the patient is alive and free of 
disease.
Samples, histopathologic and immunohistochemical analyses
All diagnostic blocks and slides of both breast adenoid cystic carcinomas were centrally 
reviewed by four pathologists (NF, EG-R, IOE & JSR-F) and morphologically distinct areas 
of each tumor were identified. Approval was obtained from the Institutional Review Boards 
(IRB) of the authors’ institutions, and written consent was obtained according to the IRB-
approved protocols. Four µm-thick sections from representative formalin-fixed paraffin-
embedded (FFPE) tissues of both cases were subjected to immunohistochemical analysis 
using antibodies against ER, PR, Ki67, HER2, cytokeratin 7, p63, c-KIT and MYB, 
Fusco et al. Page 3
Mod Pathol. Author manuscript; available in PMC 2017 February 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
following previously described protocols (Supplementary Table 1).22,23 Positive and 
negative controls were included in each slide run. All immunohistochemical stains were 
independently analyzed by four of the authors (NF, FCG, EG-R & JSR-F) and the 
immunohistochemical characteristics of each morphologically distinct area of the tumors 
were evaluated. ER, PR, and HER2 status were assessed following the American Society of 
Clinical Oncology (ASCO)/ College of American Pathologists (CAP) guidelines.24,25 The 
Ki67 index was assessed according to the recommendations of the International Ki67 in 
Breast Cancer working group.26 For cytokeratin 7 and p63 the percentage of tumor cells 
within a given component was recorded, while for c-Kit the immunoreactive score (IRS) was 
calculated according to Remmele and Stegner.27 Discordant results were resolved on a 
multi-headed microscope.
Fluorescence in situ hybridization (FISH)
FISH was performed on 4 µm-thick FFPE sections using a three-color probe mix consisting 
of bacterial artificial chromosomes (BACs) for 5′ MYB (RP11-614H6, RP11-104D9; 
green), 3′ MYB (RP11-323N12, RP11-1060C14; orange) and 3′ NFIB (RP11-413D24, 
RP11-589C16; red) using validated protocols at the Memorial Sloan Kettering Cancer 
Center (MSKCC) Molecular Cytogenetics Core as previously described.23,28 For analysis, at 
least 50 non-overlapping, interphase nuclei of morphologically unequivocal neoplastic cells 
were analyzed, and components with ≥15% of cells displaying at least one 5’MYB-3’NFIB 
fusion signal were considered fusion-positive.23
Microdissection and DNA extraction
Eight µm-thick sections of representative FFPE blocks of tumor and normal breast tissue 
from each case were stained with nuclear fast red. The morphologically distinct components 
of each case (i.e. AdCC1, trabecular adenoid cystic carcinoma and high-grade triple-negative 
breast cancer; AdCC2, cribriform adenoid cystic carcinoma, solid adenoid cystic carcinoma 
and high-grade triple-negative breast cancer) were microdissected separately with a sterile 
needle under a stereomicroscope (Olympus SZ61) to ensure >80% of tumor cell content. 
Furthermore, the normal tissue was microdissected to be devoid of any neoplastic cells as 
previously described.29,30 Genomic DNA from each tumor component and matched normal 
tissue was extracted using the DNeasy Blood & Tissue Kit (Qiagen), according to the 
manufacturer’s instructions, and quantified using the Qubit 2.0 Fluorometer (Invitrogen, Life 
Technologies).
Reverse transcription PCR
The MYB-NFIB fusion transcript variants, including MYB exon 14 fused to NFIB exons 8 
or 9, were defined in each tumor component by reverse transcription PCR (RT-PCR) as 
previously described.13,23 Total RNA was extracted from the different components of each 
case from FFPE sections using the RNeasy FFPE Kit (Qiagen) and reverse transcribed 
(SuperScript III Reverse Transcriptase; Invitrogen), and PCRs performed to detect specific 
fusion transcripts as previously described (primers see Supplementary Table 2).13,31 A breast 
adenoid cystic carcinoma known to harbor a MYB-NFIB fusion gene was employed as a 
positive control.7 All experiments were performed in duplicate.
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Targeted massively parallel sequencing and amplicon re-sequencing
Tumor and normal DNA samples were subjected to targeted capture massively parallel 
sequencing at the MSKCC Integrated Genomics Operation, using the MSK Integrated 
Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) sequencing assay 
targeting all exons and selected introns of 341 key cancer genes,32,33 as well as a sequencing 
assay targeting all exons of 254 genes recurrently mutated in breast cancer and related to 
DNA repair34 (Supplementary Table 3). Of the 595 genes captured, 107 genes were common 
to both targeted capture sequencing assays (i.e. 488 unique genes; Supplementary Table 3). 
Targeted sequencing on an Illumina HiSeq2500 was performed as previously described.32,34 
Reads were aligned to the reference human genome GRCh37 using the Burrows-Wheeler 
Aligner,35 and local realignment, duplicate removal and base quality recalibration were 
performed using the Genome Analysis Toolkit36 and picard (http://broadinstitute.github.io/
picard/). Somatic single nucleotide variants were detected by MuTect,37 small insertion and 
deletions by Varscan 2 and Strelka,38,39 and further curated by manual inspection. Single 
nucleotide variants and small insertion and deletions located outside of the target regions, 
with mutant allelic fraction of <1% and/or supported by <5 reads were disregarded.13 We 
further excluded single nucleotide variants and small insertion and deletions for which the 
tumor mutant allelic fraction was <5 times that of the matched normal mutant allelic 
fraction, as well as single nucleotide variants and small insertion and deletions found at >5% 
global minor allele frequency of dbSNP (build 137).13
The 107 genes common to both targeted capture sequencing assays were used for cross-
validation. In addition, selected mutations identified by target capture sequencing present in 
only one sequencing assay were validated independently in each of the distinct 
morphological components using amplicon re-sequencing (for primers, see Supplementary 
Table 4) on an Illumina MiSeq using a 150×150 chemistry in the MSKCC Integrated 
Genomics Operation as previously described.13 The depth of coverage was 5,230×–32,321×. 
The overall validation rate of 28 non-synonymous somatic mutations assessed was 96.4% 
(27/28); a MYB mutation found to be absent by targeted capture massively parallel 
sequencing in one sample (AdCC2, solid component) was identified to be present by high-
depth amplicon re-sequencing (Supplementary Table 5). Only validated mutations were 
employed for subsequent analyses.
The potential functional effect of each single nucleotide variant was defined using a 
combination of MutationTaster40 and CHASM41 as previously described.42 Genes affected 
by non-passenger mutations were further annotated according to their presence in three 
cancer gene datasets, Kandoth et al.,43 the Cancer Gene Census44 and Lawrence et al.45
Sequencing data have been deposited to the NCBI Sequence Read Archive under accession 
SRP068515.
Copy number analysis
For whole genome copy number analysis, DNA from each component of each case was 
hybridized to OncoScan FFPE v3 arrays (Affymetrix) separately as previously described.46 
Raw data files were loaded into Nexus Express for OncoScan analysis software 
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(BioDiscovery) and analyzed using ASCAT47 as implemented in the Nexus Express for 
OncoScan software. Regions of copy number gains/losses, amplifications and homozygous 
deletions were generated based on the ploidy and purity adjusted modal copy numbers from 
ABSOLUTE (v1.0.6),48 where segments of modal copy number 0 were considered 
homozygously deleted, modal copy number >0 and ≤ ploidy−1 considered lost, modal copy 
number ≥ ploidy considered gained and modal copy number ≥ ploidy considered amplified. 
For each case, dimension reduction was performed using the BioConductor package 
CGHregions49 to generate a matrix of collapsed copy number regions. OncoScan array data 
have been deposited to the NCBI Gene Expression Omnibus under the accession GSE79052.
Cancer cell fraction
The cancer cell fraction of each validated mutation was inferred using the number of reads 
supporting the reference and the alternate alleles, and the segmented Log ratios from 
OncoScan arrays as input for ABSOLUTE (v1.0.6).48 Solutions from ABSOLUTE were 
manually reviewed as recommended.48,50 A mutation was classified as clonal if its 
probability of being clonal was >50%50 or if the lower bound of the 95% confidence interval 
of its cancer cell fraction was >90%;29 mutations that did not meet the above criteria were 
considered subclonal.
Phylogenetic tree construction
Phylogenetic tree construction was performed using somatic mutations and copy number 
alterations. For somatic mutations, binary presence/absence matrices based on the non-
synonymous and synonymous somatic mutations were constructed. For copy number 
alterations, the matrix of collapsed copy number regions was used. Maximum parsimony 
trees for the two cases were constructed as previously described.51 A starting tree was 
constructed using the Neighbor-joining method and Hamming distance and optimized using 
the parsimony ratchet method52 implemented in the R package Phangorn.53 Trees were 
rooted at the hypothetical germline where all somatic genetic alterations are absent. Branch 
lengths were determined according to the ACCTRAN criterion as implemented in the 
Phangorn package53 and are drawn to scale.
RESULTS
Histologic and immunohistochemical features of adenoid cystic carcinoma and associated 
high-grade triple-negative breast cancer of no special type
Based on histology and immunohistochemical findings, both cases were classified as bona 
fide adenoid cystic carcinomas (Figures 1 and 2, Table 1). In addition to areas unequivocally 
diagnostic of adenoid cystic carcinoma, both cases displayed a minor component of high-
grade triple-negative breast cancer of no special type. Case 1 (AdCC1) was an adenoid 
cystic carcinoma with infiltrative borders characterized by a predominantly trabecular 
proliferation of a dual population of neoplastic cells: the more abundant small cells with 
angular dark nucleus and scant cytoplasm, and cuboidal-to-polyhedral cells with more 
abundant cytoplasm, which often lined the duct-like structures. Both cell types displayed 
relatively bland and uniform nuclei, devoid of conspicuous pleomorphism. Mitotic figures 
were infrequent (1 and 6 per 10 high power fields (0.238mm2) in the adenoid cystic 
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carcinoma and high-grade triple-negative breast cancer components, respectively). At the 
periphery of the lesion, a component of high-grade triple-negative breast cancer of no 
special type comprising approximately 20% of the lesion was identified (Figure 1). This area 
was composed of larger, more atypical cells with larger nuclei, more conspicuous nucleoli 
and scant cytoplasm. The high-grade triple-negative breast cancer displayed a higher 
proportion of cells displaying an epithelial rather than myoepithelial immunohistochemical 
profile (Figure 1, Table 1). Consistent with this observation, a decreased cell population with 
myoepithelial differentiation has been consistently described in high-grade breast adenoid 
cystic carcinomas and transformed adenoid cystic carcinoma of the salivary glands.17,54
Case 2 (AdCC2) was composed of a single mass with infiltrative borders, encompassing a 
dual population of cells similar to those found in AdCC1, but arranged in two distinct 
histologic patterns, solid and cribriform. The solid component comprised approximately 
70% of the entire lesion, while the cribriform component accounted for approximately 20%. 
In both components, a dual population of cells similar to that described in AdCC1 was 
observed. In continuity with the solid component, an area composed of cells with more 
abundant cytoplasm, and larger, more pleomorphic nuclei with conspicuous nucleoli was 
observed. This high-grade area, where the neoplastic cells were arranged in solid sheets and 
abortive duct-like structures, was classified as high-grade triple-negative breast cancer of no 
special type (Figure 2, Table 1). Akin to AdCC1, an increased ratio of cells displaying 
epithelial rather than myoepithelial phenotype was observed in the solid and high-grade 
triple-negative breast cancer components (Figure 2, Table 1). As expected, Ki67 levels were 
higher in the high-grade triple-negative breast cancer component as compared to the 
cribriform and solid components (Table 1).
Adenoid cystic carcinoma and associated high-grade triple-negative breast cancer of no 
special type harbor the MYB-NFIB fusion gene
To define whether the high-grade triple-negative breast cancer components of AdCC1 and 
AdCC2 would be related to the bona fide areas of adenoid cystic carcinoma, we investigated 
the presence of the MYB-NFIB fusion gene in the adenoid cystic carcinoma and high-grade 
triple-negative breast cancer components of each case by means of FISH and RT-PCR. FISH 
analysis revealed the presence of the MYB-NFIB fusion gene in both the trabecular and the 
high-grade triple-negative breast cancer component of AdCC1 (Figure 3). RT-PCR analysis 
confirmed the expression of the MYB-NFIB transcript in both components of AdCC1, and 
showed that it involved MYB exon 14 linked to NFIB exon 8c (Supplementary Figure 1). 
All components of AdCC2, the cribriform adenoid cystic carcinoma, solid adenoid cystic 
carcinoma and high-grade triple-negative breast cancer, harbored the MYB-NFIB fusion 
gene as defined by FISH analysis (Figure 4). Akin to AdCC1, RT-PCR revealed the 
expression of the corresponding fusion transcript MYB-NFIB in all neoplastic areas of case 
AdCC2, involving MYB exon 14 linked to NFIB exon 8c (Supplementary Figure 1). These 
data provide evidence consistent with the notion that the high-grade triple-negative breast 
cancer components of both cases are likely clonally related to their respective bona fide 
adenoid cystic carcinomas, and may represent high-grade transformation of the adenoid 
cystic carcinomas.
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Adenoid cystic carcinoma and associated high-grade triple-negative breast cancer of no 
special type display similar patterns of gene copy number alterations
Consistent with the presence of the MYB-NFIB fusion gene in the bona fide adenoid cystic 
carcinoma and the high-grade triple-negative breast cancer components of both adenoid 
cystic carcinomas studied here, gene copy number analysis by OncoScan molecular 
inversion probe arrays revealed the lack of complex gene copy number alterations in the 
high-grade triple-negative breast cancer components and low levels of genomic instability. In 
fact, the gene copy number profiles of the high-grade triple-negative breast cancer 
components were highly similar to those of the respective adenoid cystic carcinoma 
components in both cases (Figures 3b and 4b).
Both the trabecular adenoid cystic carcinoma and high-grade triple-negative breast cancer 
components of AdCC1 had few gene copy number alterations. A loss at 6q23.3-6q27 was 
found in both components (Figure 3b), and this genomic locus is consistent with the regions 
previously described as recurrently lost in breast adenoid cystic carcinomas7 and in salivary 
gland adenoid cystic carcinomas with high-grade transformation.54 All components of 
AdCC2 displayed losses of chromosomes 4, 7, 14 and X (Figure 4b). The high-grade triple-
negative breast cancer component of AdCC2 also harbored a subclonal gain of chromosome 
21. These findings provide circumstantial evidence for the clonal relatedness of the different 
adenoid cystic carcinoma and high-grade triple-negative breast cancer components in the 
two breast adenoid cystic carcinomas with high-grade transformation studied here, and 
confirm the existence a subset of high-grade triple-negative breast cancers harboring few 
copy number alterations.55
Progression from adenoid cystic carcinoma to high-grade triple-negative breast cancer of 
no special type involves the selection of clones and the acquisition of additional genetic 
alterations
To define the landscape of somatic mutations of the two adenoid cystic carcinomas and their 
associated high-grade triple-negative breast cancers, we subjected the DNA extracted from 
the separately microdissected adenoid cystic carcinoma and high-grade triple-negative breast 
cancer components to massively parallel sequencing targeting all exons of 488 genes, 
including clinically actionable genes, the most frequently mutated genes in breast cancer and 
DNA repair-related genes (see Methods). The tumor samples were sequenced to a median 
depth of 258× (205×–352×).
Common forms of high-grade triple-negative breast cancer and basal-like breast cancer have 
been shown to have high mutation rates, and to harbor mutations in TP53 in >80% of cases, 
as well as mutations in PIK3CA, and DNA repair-related genes.14–16 None of the adenoid 
cystic carcinomas and their respective high-grade triple-negative breast cancer components 
studied here harbored somatic mutations affecting TP53, PIK3CA and/ or DNA repair genes 
(Figures 3c and 4c; Supplementary Table 5). This repertoire of somatic mutations is 
consistent with those of pure adenoid cystic carcinomas of the breast, which have been 
shown to be characterized by low mutation rates and lack of mutations affecting TP53, 
PIK3CA and DNA repair genes.13 These findings are consistent also with the observations 
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made by Shah et al., who reported on a subset of triple-negative breast cancers lacking TP53 
mutations and displaying a limited number of somatic mutations.15
In AdCC1, seven and five somatic mutations were identified in the trabecular adenoid cystic 
carcinomas and high-grade triple-negative breast cancer components, respectively (Figure 
3c, Supplementary Table 5). Notably, mutations including those affecting bona fide cancer 
genes such as ERBB2 and FGFR1 were subclonal, indicating the presence of intra-tumor 
genetic heterogeneity. Four of the mutations identified targeted two genes, namely EP300 
and NOTCH1. A nonsense mutation in EP300 (R86*) and a clonal frameshift mutation in 
NOTCH1 (G2430fs) were restricted to the trabecular adenoid cystic carcinoma component, 
with cancer cell fractions of 53% and 97%, respectively, whereas the additional EP300 
R202* and NOTCH1 D2442fs mutations were detected in both components (Figure 3c), 
providing evidence suggestive of a convergent phenotype. Interestingly, the subclonal EP300 
R202* and the NOTCH1 D2442fs mutations in the trabecular adenoid cystic carcinoma 
became clonal in the high-grade triple-negative breast cancer component. In addition, there 
was enrichment in the cancer cell fractions of the FGFR1 and ERBB2 mutations from 6% 
and 7% in the trabecular adenoid cystic carcinoma to 48% and 16% in the high-grade triple-
negative breast cancer, respectively. These data suggest that a clonal shift, and potentially 
clonal selection, occurred in the progression from the adenoid cystic carcinoma to high-
grade triple-negative breast cancer in this case (Figure 3d).
In AdCC2, only two KMT2C mutations (E3717K and K339N) were found in the cribriform 
adenoid cystic carcinoma component. In fact, the KMT2C E3717K mutation was identified 
as the founder genetic event, being clonal and present in all cancer cells of the cribriform 
adenoid cystic carcinoma, the solid adenoid cystic carcinoma and high-grade triple-negative 
breast cancer components. Akin to AdCC1, a second but subclonal missense mutation 
affecting the same gene (KMT2C K339N) was found in all components, with cancer cell 
fractions ranging from 12% to 40%, indicating the presence of intra-tumor genetic 
heterogeneity also in this case. In addition, a validated subclonal MYB mutation was 
restricted to the solid adenoid cystic carcinoma and the high-grade triple-negative breast 
cancer components. Moreover, subclonal mutations in STAG2, KDM6A and CDK12 were 
found to be restricted to the high-grade triple-negative breast cancer, with cancer cell 
fractions of 36–49%. These data suggest that in this AdCC2 case progression from adenoid 
cystic carcinoma to high-grade triple-negative breast cancer may have occurred through the 
acquisition of additional genetic alterations (Figure 4c and 4d).
Taken together, our findings demonstrate that in both cases, the high-grade triple-negative 
breast cancer components were clonally related to the bona fide adenoid cystic carcinomas, 
providing support to the notion that morphologically unequivocal adenoid cystic carcinomas 
associated with high-grade triple-negative breast cancers may display intra-tumor genetic 
heterogeneity, and that in the progression from adenoid cystic carcinoma to high-grade 
triple-negative breast cancer, clonal shifts, and potentially clonal selection, may take place.
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DISCUSSION
Adenoid cystic carcinomas of the breast are rare neoplasms that despite being of triple-
negative phenotype usually have an indolent clinical behavior. High-grade transformation 
can occur and is associated with aggressive clinical behavior and poor response to systemic 
therapies,19,20 however guidelines for the management of this particular subset of patients 
have yet to be fully implemented.
Here we performed a genetic analysis of two breast adenoid cystic carcinomas with high-
grade triple-negative breast cancer of no special type components and found that adenoid 
cystic carcinomas associated with high-grade triple-negative breast cancer may be composed 
of multiple clones at diagnosis, consistent with previous observations by our group,13 and 
that progression to high-grade triple-negative breast cancer may occur through clonal 
selection and/ or the acquisition of additional genetic events. Furthermore, in this 
progression from a low-grade trabecular or cribriform adenoid cystic carcinoma to a high-
grade triple-negative breast cancer of no special type, we documented the presence of the 
MYB-NFIB fusion gene not only in the adenoid cystic carcinoma components, but also in 
the high-grade triple-negative breast cancer areas of both cases.
The prevalence of the MYB-NFIB fusion gene in breast adenoid cystic carcinomas has been 
reported to range from 23% to 100%.6,7,12,13,21,56 Recently, D’Alfonso et al.21 reported on 
the solid variant of breast adenoid cystic carcinomas with basaloid features and confirmed 
that this high-grade variant may harbor MYB rearrangements, although at lower frequencies 
(2/16; 12.5%). Here we demonstrate that high-grade triple-negative breast cancer of no 
special type associated with bona fide adenoid cystic carcinomas may also be underpinned 
by the MYB-NFIB fusion gene. Further studies analyzing larger numbers of breast adenoid 
cystic carcinomas are warranted to determine the prevalence of MYB-NFIB fusion gene in 
this histologic context.
Several studies including small cohorts of patients with salivary gland adenoid cystic 
carcinomas54,57,58 suggested that TP53 inactivation17,54,57 and/ or amplification of 8q24.12-
q24.13 encompassing MYC57 may play a role in high-grade transformation of these lesions. 
Neither breast adenoid cystic carcinomas analyzed here harbored TP53 mutations and/ or 
MYC amplification. Our previous analyses of breast adenoid cystic carcinomas revealed that 
these lesions harbor somatic mutations that affect cancer-related genes, but lack TP53 and 
PIK3CA mutations found in common forms of high-grade triple-negative breast cancer and 
that the genes mutated in breast adenoid cystic carcinomas converge into several functional 
categories including chromatin remodeling and signaling pathway genes amongst others.13 
Consistent with these findings, we found that the adenoid cystic carcinomas studied here 
harbored mutations in chromatin remodeling genes (i.e. EP300, AdCC1; KMT2C, KDM6A, 
AdCC2) and in signaling pathway genes (i.e. ERRB2, FGFR1 and RPS6KB2, AdCC1), as 
well as in MYB itself (AdCC2). Interestingly, whilst salivary gland adenoid cystic 
carcinomas have been reported to harbor recurrent mutations affecting NOTCH signaling 
pathway genes, including NOTCH1, NOTCH2 and SPEN,28,59 these genes were not found 
to be altered in 12 classical tubular/ cribriform breast adenoid cystic carcinomas previously 
studied.13 In contrast, in one of the adenoid cystic carcinomas with high-grade 
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transformation (AdCC1) analyzed here, two distinct NOTCH1 frameshift mutations were 
identified, one of which was restricted to the trabecular adenoid cystic carcinoma component 
(G2430fs) whereas the second NOTCH1 mutation (D2442fs) was subclonal in the trabecular 
adenoid cystic carcinoma component and became clonal in the high-grade triple-negative 
breast cancer of no special type. This clonal shift was also observed for mutations affecting 
the histone acetyltransferase EP300 in AdCC1: the EP300 R86* mutation was restricted to 
the trabecular adenoid cystic carcinoma component while the EP300 R202* mutation was 
subclonal in the adenoid cystic carcinoma component but clonal in the high-grade triple-
negative breast cancer component. In AdCC2, high-grade transformation was likely driven 
by the acquisition of additional mutations including a CDK12 frameshift mutation or by the 
selection of a clone harboring these alterations but not sampled in our extensive sampling of 
the distinct components of the adenoid cystic carcinoma. A suclonal MYB R190H somatic 
mutation was detected in the solid adenoid cystic carcinoma and in the high-grade triple-
negative carcinoma components of AdCC2. One could posit that this somatic mutation may 
have conferred a growth and/ or survival advantage; it should be noted, however, that this 
mutation was present in a minor subclone of the solid adenoid cystic carcinoma and high-
grade triple-negative carcinoma components, was considered by multiple mutation function 
predictors as a passenger/ non-deleterious mutation, and has not been previously 
documented in the Catalog of Somatic Mutations in Cancer44 and the cBioPortal database 
(www.cBioPortal.org; accessed on May 30th 2016)60. Our findings provide evidence to 
suggest that the genetic events driving progression of breast adenoid cystic carcinomas are 
heterogeneous; however as these involve mutations in potentially actionable cancer genes, 
comprehensive sequencing analyses are warranted to identify therapeutic targets in adenoid 
cystic carcinomas with high-grade transformation.
Triple-negative breast cancers have been shown to be heterogeneous at the genetic level with 
some tumors harboring only a few non-synonymous somatic mutations.14–16 Based on the 
findings of our study, one may hypothesize that the high-grade transformation of low-grade 
triple-negative breast cancers such as adenoid cystic carcinomas may account for a subset of 
triple-negative breast cancers with low levels of copy number alterations and few somatic 
mutations.15,55 Further studies are warranted to characterize genetically stable triple-
negative breast cancers thought to be of common type.
To define whether the MYB-NFIB fusion gene would be present in a subset of common-type 
triple-negative breast cancers, we searched for the presence of breast cancers in The Cancer 
Genome Atlas (TCGA) data set harboring the MYB-NFIB fusion using the TCGA Fusion 
gene Data Portal (http://54.84.12.177/PanCanFusV2/). We identified one invasive breast 
cancer from the TCGA dataset (case TCGA-A1-A0SB-01A), which according to the 
pathology report provided in the cBioPortal (www.cBioPortal.org)60 is a breast adenoid 
cystic carcinoma.
This study has several limitations. First, owing to the rarity of breast adenoid cystic 
carcinomas with progression to high-grade triple-negative breast cancer, our sample size is 
small. Second, given the limited amount of DNA extracted from each component of each 
case, we were unable to retrieve sufficient DNA for whole exome or whole genome 
sequencing; however, the use of two independent targeted capture massively parallel 
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sequencing assays allowed for a validation of somatic mutations affecting 107 genes, in 
addition to the targeted amplicon validation of the mutations identified in AdCC1 and 
AdCC2. Third, owing to the fact that these cases were obtained from distinct institutions, we 
were unable to ascertain accurately the clinical behavior of the high-grade triple-negative 
breast cancer components of these cases. Despite these limitations, here we demonstrate that 
breast adenoid cystic carcinomas with high-grade transformation may be underpinned by the 
MYB-NFIB fusion gene and display intra-tumor genetic heterogeneity. Progression from 
conventional adenoid cystic carcinoma to high-grade triple-negative breast cancer of no 
special type involves the selection of specific clones and/ or acquisition of mutations in bona 
fide cancer genes. This morphologic and genetic heterogeneity should be taken into account 
when performing histologic analyses of breast biopsies, given that the recognition of 
transformed areas of high-grade triple-negative breast cancer of no special type within an 
adenoid cystic carcinoma of the breast might allow for a more precise prognostication and 
the identification of potentially actionable genetic alterations.
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Figure 1. Histologic and immunohistochemical features of an adenoid cystic carcinoma with 
high-grade transformation (case AdCC1)
Low-power view of an adenoid cystic carcinoma (a) with diffuse c-Kit immunoreactivity 
(b), which was composed of a predominant trabecular component (c) and a minor 
component of high-grade triple-negative breast cancer of no special type (f). Cytokeratin 7 
(d, g) and p63 (e, h) expression highlights the populations with epithelial and myoepithelial 
phenotype in the trabecular and high-grade components, respectively.
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Figure 2. Histologic and immunohistochemical features of an adenoid cystic carcinoma with 
high-grade transformation (case AdCC2)
Low-power view of an adenoid cystic carcinoma (a) with diffuse c-Kit immunoreactivity 
(b), which was composed of three distinct components, including a cribriform (c), a solid (f) 
and a minor component high-grade triple-negative breast cancer of no special type (i). 
Cytokeratin 7 (d, g, j) and p63 (e, h, k) expression highlights the populations with epithelial 
and myoepithelial phenotype, respectively.
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Figure 3. Genomic profiling of an adenoid cystic carcinoma with high-grade transformation 
(case AdCC1)
(a) FISH analysis using a three-color MYB–NFIB probe, with 5’ MYB (green), 3’ MYB 
(orange) and 3’ NFIB (red), showing the presence of the fusion gene in the trabecular 
adenoid cystic carcinoma and high-grade triple-negative breast cancer components (white 
arrows). (b) The gene copy number profiles of the trabecular and high-grade triple-negative 
breast cancer components are highly similar. In the genome plots, Log2 ratios were plotted 
on the y-axis according to their genomic positions indicated on the x-axis. (c) Diagram 
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depicting the somatic mutations identified in the trabecular and high-grade triple-negative 
breast cancer components. Cancer cell fractions are shown, which are the estimated 
percentage of cancer cells harboring a given somatic mutation, and are color-coded 
according to the legend. Clonal somatic mutations are marked by an orange border. In the 
progression from the trabecular adenoid cystic carcinoma to the high-grade triple-negative 
breast cancer, the subclonal mutations affecting EP300 and NOTCH1 became clonal. (d) 
Phylogenetic tree depicting the evolution of the trabecular adenoid cystic carcinoma and the 
high-grade triple-negative components, where the colored branches represent each of the 
subclones identified. The length of the branches is representative of the number of mutations 
and copy number alterations that distinguishes a given clone from its ancestral clone;51 
somatic genetic alterations that define a given subclone are illustrated along the branches.
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Figure 4. Genomic profiling of an adenoid cystic carcinoma with high-grade transformation 
(case AdCC2)
(a) FISH analysis using a three-color MYB–NFIB probe, with 5’ MYB (green), 3’ MYB 
(orange) and 3’ NFIB (red), showing the presence of the fusion gene in the cribriform 
adenoid cystic carcinoma, solid adenoid cystic carcinoma and high-grade triple-negative 
breast cancer components (white arrows). (b) The gene copy number profiles of the 
cribriform adenoid cystic carcinoma, solid adenoid cystic carcinoma and high-grade triple-
negative breast cancer are highly similar. In the genome plots, Log2 ratios were plotted on 
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the y-axis according to their genomic positions indicated on the x-axis. (c) Diagram 
depicting the somatic mutations identified in the cribriform adenoid cystic carcinoma, solid 
adenoid cystic carcinoma and high-grade triple-negative breast cancer components. Cancer 
cell fractions are shown, which are the estimated percentage of cancer cells harboring a 
given somatic mutation, and are color-coded according to the legend. Clonal somatic 
mutations are marked by an orange border. In the progression from the cribriform adenoid 
cystic carcinoma to the high-grade triple negative breast cancer, additional subclonal 
mutations were acquired. (d) Phylogenetic tree depicting the evolution of the cribriform 
adenoid cystic carcinoma, solid adenoid cystic carcinoma and the high-grade triple-negative 
components, where the colored branches represent each of the subclones identified. The 
length of the branches is representative of the number of mutations and copy number 
alterations that distinguishes a given clone from its ancestral clone;51 somatic genetic 
alterations that define a given subclone are illustrated along the branches.
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